Amylyx signs avexitide manufacturing deal with Bachem and a $30 million Polypeptide term sheet
Amylyx entered a manufacturing and supply agreement with Bachem on September 8, 2026, and a term sheet with Polypeptide Group on September 1, 2026, to supply its long-term commercial needs for avexitide drug substance, if approved. The company will pay Polypeptide a $30 million upfront fee for capacity reservation, and both suppliers are non-exclusive.
Key points
- Bachem Manufacturing Agreement signed September 8, 2026, with an initial five-year term that renews automatically for three-year periods
- Polypeptide Term Sheet signed September 1, 2026, with a $30 million upfront fee for capacity reservation; a definitive agreement is still to be negotiated
- Both agreements require minimum annual purchases beginning in 2028, with supply prices adjusted annually
- Full agreements will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.